ShareholdingMay 4, 2026, 04:15 PM
Acurx Pharmaceuticals Registers 1.65M Shares for Resale by Holders
AI Summary
Acurx Pharmaceuticals, Inc. filed an S-1 registration statement for the resale of up to 1,650,170 shares of common stock by selling stockholders. These shares are issuable upon the exercise of series H warrants, which have an exercise price of $2.78 per share and were issued in a concurrent private placement on April 15, 2026. The company will not receive proceeds from the resale, but could receive approximately $4.6 million if all warrants are exercised for cash. Additionally, Acurx recently completed a registered direct offering, raising approximately $2.5 million, and announced a new clinical trial program for ibezapolstat in recurrent C. difficile infection.
Key Highlights
- Selling stockholders to resell up to 1,650,170 common shares.
- Shares are issuable upon exercise of series H warrants at $2.78 per share.
- Acurx will not receive proceeds from share sales, but could get $4.6M if warrants are cash-exercised.
- Company recently raised approximately $2.5M gross proceeds in a registered direct offering.
- New clinical trial program for ibezapolstat in recurrent C. difficile infection (rCDI) announced.
- Pilot trial for rCDI to enroll up to 20 patients, with activities starting Q2 2026.
- Acurx common stock trades on Nasdaq under "ACXP", last reported sale price $2.16.
- Company is an "emerging growth company" and "smaller reporting company".
Price Impact
More from ACXP